Early reduction in ctDNA predicts survival in lung and bladder cancer patients treated with durvalumab.
CONCLUSIONS: ctDNA VAF changes are strongly correlated with duration of treatment, antitumor activity and clinical outcomes in NSCLC and UC. Early on-treatment reduction in ctDNA VAF may be a useful predictor of long-term benefit from immunotherapy. Prospective studies should validate these findings and the value of utilizing early changes in ctDNA for therapeutic decision-making by identifying non-responders to checkpoint inhibitor monotherapies and guiding combination therapies.
PMID: 30093454 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Raja R, Kuziora M, Brohawn P, Higgs BW, Gupta A, Dennis PA, Ranade K Tags: Clin Cancer Res Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Genetics | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Radiography | Study